Expertise in
22
conditions

Dr. Douglas S. Hawkins

Hematology | Oncology
Seattle Children's Hospital
4800 Sand Point Way NE, 
Seattle, WA 
Clinical Trials:Currently Recruiting for 5 Trials
Accepting New Patients
Offers Telehealth
Expertise in
22
conditions
Seattle Children's Hospital
4800 Sand Point Way NE, 
Seattle, WA 

Overview

Douglas Hawkins is a Hematologist and an Oncologist practicing medicine in Seattle, Washington.

Dr. Hawkins is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, Osteosarcoma, Osteotomy, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 234 peer reviewed articles and participating in 79 clinical trials. Dr. Hawkins is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in WA

Languages Spoken

English
German

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Community Health
  • EPO
  • HMO
PacificSource
  • PPO
Premera
  • EPO
  • PPO

Locations

Seattle Children's Hospital
4800 Sand Point Way NE, Seattle, WA 98105

Additional Areas of Focus

Dr. Hawkins has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

76 Clinical Trials

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Other
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Busulfan, Carboplatin, Cisplatin, Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Etoposide Phosphate, Isotretinoin, Melphalan Hydrochloride, Sargramostim, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological
Study Drugs: Axitinib, Nivolumab
Study Phase: Phase 2
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study
Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study
Enrollment Status: Completed
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
Study Phase: Not Applicable
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
View 5 Less Clinical Trials

234 Total Publications

Long-Term Analysis of Patients With Ewing Sarcoma Included in the Euro-EWING99 Study.
Long-Term Analysis of Patients With Ewing Sarcoma Included in the Euro-EWING99 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 31, 2026
Similar Doctors
Expertise in
24
conditions
Dr. Sarah S. Leary
Hematology | Oncology
Expertise in
24
conditions
Dr. Sarah S. Leary
Hematology | Oncology
Referral may be required

Seattle Children's Hospital

4800 Sand Point Way NE, 
Seattle, WA 
 (0.1 miles away)
206-987-2106
Languages Spoken:
English, Castilian, French, Hindi, Mandarin, Punjabi, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Sarah Leary is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Leary is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Medulloblastoma, Glioma, Gliomatosis Cerebri, Brain Tumor, and Bone Marrow Aspiration. Dr. Leary is currently accepting new patients.

Expertise in
11
conditions
Dr. James M. Olson
Hematology | Oncology
Expertise in
11
conditions
Dr. James M. Olson
Hematology | Oncology
Referral may be required

Seattle Children's Hospital

4800 Sand Point Way NE, 
Seattle, WA 
 (0.1 miles away)
206-987-2106
Languages Spoken:
English, Afrikaans, Korean, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

James Olson is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Olson is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Posterior Fossa Tumor, and Glioma. Dr. Olson is currently accepting new patients.

Expertise in
8
conditions
Dr. Yoshihiro Inamoto
Hematology | Oncology
Expertise in
8
conditions
Dr. Yoshihiro Inamoto
Hematology | Oncology
Referral may be required

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (3.3 miles away)
206-667-2898
Languages Spoken:
English

Yoshihiro Inamoto is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Inamoto is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Adult T-Cell Leukemia, Bone Marrow Transplant, and Bone Graft.

Frequently Asked Questions about Dr. Douglas S. Hawkins

How do I make an appointment with Dr. Douglas S. Hawkins?

You can book an appointment with Dr. Douglas S. Hawkins by calling their office at 206-987-2000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Douglas S. Hawkins a top-rated expert for Rhabdomyosarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Douglas S. Hawkins is classified as an Elite expert for Rhabdomyosarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Douglas S. Hawkins specialize in?

While Dr. Douglas S. Hawkins is a Hematology, they have specific expertise in Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, and Osteosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Douglas S. Hawkins participate in research or clinical trials?

Yes. Dr. Douglas S. Hawkins has published 234 articles and abstracts on conditions like Rhabdomyosarcoma. You can view a list of Dr. Douglas S. Hawkins's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Douglas S. Hawkins accept my insurance?

Dr. Douglas S. Hawkins accepts most major insurance plans, including Community Health and PacificSource. We recommend calling the office directly at 206-987-2000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hawkins's expertise for a condition
ConditionClose
View All 18 Advanced Conditions
View All 37 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile